MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
34.87
+0.89
+2.62%
After Hours: 34.86 -0.01 -0.03% 19:59 09/04 EDT
OPEN
33.75
PREV CLOSE
33.98
HIGH
34.95
LOW
33.56
VOLUME
1.40M
TURNOVER
--
52 WEEK HIGH
43.15
52 WEEK LOW
22.96
MARKET CAP
4.07B
P/E (TTM)
-7.4793
1D
5D
1M
3M
1Y
5Y
1D
MongoDB, Credo Technology Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Benzinga · 3d ago
Weekly Report: what happened at VKTX last week (0824-0828)?
Weekly Report · 5d ago
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?
NASDAQ · 08/28 15:30
Corbus Pharmaceuticals Holdings Inc. Stock Rises 5.8%, Outperforms Peers
Dow Jones · 08/25 20:32
Der Aktionaer editor speculates on timing of Viking Therapeutics data
TipRanks · 08/24 17:45
Weekly Report: what happened at VKTX last week (0817-0821)?
Weekly Report · 08/24 09:22
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 5.5%, Outperforms Peers
Dow Jones · 08/21 20:33
Corbus Pharmaceuticals Holdings Inc. Stock Rises 4.0%, Outperforms Peers
Dow Jones · 08/17 20:35
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.